AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03111654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Compare the risk of a vascular event
Description: Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.~Analysis of selected therapeutic options for the prevention of AF ischemic events.
Study NCT04619056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEB-01 membrane loaded with SN-38
Description: CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.
Study NCT01178892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
Study NCT01178892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
Study NCT01178892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
Study NCT01178892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
Study NCT01178892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Omega-3
Description: The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
Study NCT01178892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
Study NCT01178892 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Yoga
Description: Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
Study NCT01178892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
Study NCT01178892 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
Study NCT01178892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Activity
Description: Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership.
Study NCT01178892 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Activity
Description: Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership.
Study NCT01178892 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Activity
Description: Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership.
Study NCT01265446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 8mg + CPC 2mg
Description: one single dose
Study NCT01265446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1mg + CPC 2mg
Description: one single dose
Study NCT02462577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: local instillation of morphine to surgical wound
Description: comparison between different drug doses effects on pain
Study NCT00812045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1236
Description: Oral tablet, 75 mg twice daily during 4 weeks
Study NCT02462577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local instillation of morphine to surgical wound
Description: comparison between different drug doses effects on pain
Study NCT00812045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00830011 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: Ten sessions of manualized CBT delivered by a PhD level psychologist
Study NCT00830011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard medical care
Description: any care recommended by physician for treatment of diabetic neuropathy including medication.
Study NCT02550418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Study NCT00382499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Intravenous Infusion
Description: 1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
Study NCT00072982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
Study NCT00072982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: borage seed oil
Description: Borage oil 13 capsules divided doses daily for 18 months
Study NCT00072982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination fish oil and borage seed oil
Description: Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
Study NCT02806206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
Study NCT02026050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraarticular dexamethasone
Description: 2ml 8 mg dexamethasone administration for intraarticular
Study NCT02026050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene dexamethasone
Description: 2ml 8 mg dexamethasone administration interscalene brachial plexus added 30 ml 0.5 % bupivacaine
Study NCT02026050 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: serum phsyologic
Description: interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
Study NCT01719614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.
Study NCT01719614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.
Study NCT02519374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (including Maltodextrin)
Study NCT02519374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROMITOR® (including Maltodextrin)
Description: Investigational product dose 1
Study NCT00557154 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard technique for venipuncture
Description: routine equipment
Study NCT06155123 — intervention group
Intervention type: DRUG
Intervention: Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)
Description: Monthly or quarterly mAbs administration for a year
Study NCT02519374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROMITOR® (including Maltodextrin)
Description: Investigational product dose 2
Study NCT02519374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROMITOR® (including Maltodextrin)
Description: Investigational product dose 3
Study NCT00655629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil ODT (STAXYN, BAY38-9456)
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
Study NCT00655629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
Study NCT01722019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tulip fiber
Description: Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.
Study NCT01722019 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VNUS closure fast
Description: Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
Study NCT00620594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Study NCT04533321 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib
Description: Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy.
Study NCT02771717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort)
Description: Budesonide (Pulmicort) - inhaled low dose inhaled steroid - I puff to be taken twice daily
Study NCT02771717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - dummy inhaler
Description: Placebo - dummy inhaler to be taken 1 puff twice daily.
Study NCT01216683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01216683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustin
Description: Given IV
Study NCT01216683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT01216683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT00600210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
Study NCT00600210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
Study NCT00600210 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.~Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions.
Study NCT03291717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridging Community Gaps Photovoice (BCGP)
Description: Participants assigned to this group will be part of the 6-month long BCGP intervention, which involves a 12- week class that meets weekly, followed by three booster sessions - one per month in the three months following the class, and up to 24 sessions of individual support as needed throughout the 6 months provided on a weekly basis either in person or by phone. The BCGP classes follow a manualized curriculum with sessions that combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing community participation goals, all refined with input from individuals with a lived experience.
Study NCT05246800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured 8-week mHealth mindfulness program
Description: The mindfulness application was developed by Minddistrict The content of the app was developed by professionals in the field of mental healthcare and based on the principles of MBSR and MBCT The app consisted of a structured program, with chapters on psycho-education on mindfulness and the importance of practicing; acting on auto-pilot, conscious attention; non-judgmental attention, awareness; doing versus being-modus; attention for breath and body, conscious response; acceptance; a mindful attitude towards thoughts; applying mindfulness in daily life and staying mindful.
Study NCT00108771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZR-02-01 Fentanyl Transdermal Matrix Patch
Description: Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
Study NCT00108771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
Study NCT00439296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-751
Description: Treatment Course 1:~Oral capsule to be given daily for 21 days at assigned dose.~Treatment Course 2:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.~Treatment Course 3:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.
Study NCT00439296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: In Treatment Course 1 only:~* 10 mg/m2/day divided BID.~* Take dexamethasone by mouth days 1-14.
Study NCT00439296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: In Treatment Course 1:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on days 4, 11 and 18.~In Treatment Course 2:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on day 15.
Study NCT00439296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: In Treatment Course 1 only:~• 60 mg/m2/day IV over 15 minutes on day 1.
Study NCT00439296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: * Given Intrathecally on day 1 of course 1 at the dose defined by age below.~  * 30 mg for patients age 1-1.99~ * 50 mg for patients age 2-2.99~ * 70 mg for patients >3 years of age~* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.~In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.
Study NCT00439296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: In Treatment Course 1:~• Given Intrathecally on day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients >9 years of age~In Treatment Course 2:~• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients >9 years of age~In Treatment Course 3:~Intrathecally on day 1 at the age-defined dose
Study NCT00439296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
Study NCT00439296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-thioguanine
Description: Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
Study NCT04243993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Calcium silicate cement
Description: Calcium silicate cement for using in endodontic treatments i.e. pulpotomy, orthograde MTA apical barrier, root perforation repair, and endodontic microsurgery.
Study NCT02466932 — intervention group
Intervention type: DEVICE
Intervention: Galilei Dual-Scheimpflug Analyzer
Description: Measuring of Anterior Segment by Galilei Dual-Scheimpflug Analyzer
Study NCT03335774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Acetate Suppository, 25 mg (Nivagen)
Description: One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
Study NCT03335774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle) Suppository (Nivagen)
Description: One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
Study NCT00491491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibritumomab tiuxetan
Description: 0.4 mCi/kg
Study NCT00491491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BEAM chemotherapy and autologous stem-cell transplantation
Study NCT00491491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BEAM chemotherapy and autologous stem-cell transplantation
Study NCT00125957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wellbutrin